A pilot clinical trial examining whether Mitoquinol initiated within 72 hours of high‑risk SARS‑CoV‑2 exposure reduces infection rates and symptom duration, including in unvaccinated and immunocompromised individuals. 

A double‑blind crossover trial examining whether 4 weeks of Mitoquinol supplementation restores immune cell bioenergetics in patients with heart failure with preserved ejection fraction (HFpEF). 

A randomised crossover trial assessing whether acute supratherapeutic doses of Mitoquinol produce any evidence of kidney injury in healthy adults, using sensitive renal biomarkers.

A 21‑day supplementation trial examining whether Mitoquinol reduces exercise‑induced nuclear and mitochondrial DNA damage without impairing adaptive training signals.

New research explores how an acute dose of MitoQ impacts claudication onset, maximal walking time, and leg artery dilation in patients with Peripheral Artery Disease.

A randomised, double-blind crossover trial assessing whether 6 weeks of Mitoquinol supplementation (20 mg/day) improves endothelial function, reduces aortic stiffness, and attenuates mitochondrial oxidative stress in healthy adults aged 60–79. 

A double‑blind trial examining whether 3 weeks of Mitoquinol supplementation during high‑intensity interval training (HIIT) enhances mitochondrial and vascular adaptation without blunting exercise‑induced redox signalling.

A controlled study assessing whether a single high dose of Mitoquinol restores flow‑mediated dilation in postmenopausal women and what this reveals about the mitochondrial basis of menopause‑related vascular ageing.